BRCA1 and breast cancer: Clinical trials have been initiated in which patients with metastatic BC are subjected to the RECAP test or both the RECAP test and BRCA1/2-like classifier before receiving PARP-inhibitor treatment (respectively: NL8099 and NCT02810743).